Jeremy Grantham's PFE Position Overview
Jeremy Grantham (via Grantham, Mayo, Van Otterloo & Co. LLC) currently holds 2.42 M shares of Pfizer Inc. (PFE) worth $61.69 M, representing 0.17% of the portfolio. First purchased in 2013-Q2, this long-term strategic position has been held for 50 quarters.
Based on 13F filings since 2013, Jeremy Grantham has maintained a long-term strategic position in PFE, representing a significant commitment to this investment thesis. Largest addition occurred in Q2 2016, adding 6.48 M shares. Largest reduction occurred in Q4 2013, reducing 20.92 M shares.
Analysis based on 13F filings available since 2013 Q2
Jeremy Grantham's Pfizer (PFE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Pfizer (PFE) Trades by Jeremy Grantham
| Period | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2013 | +58.02 M | Add 0.00% | 58.02 M | $28.01 |
| Q3 2013 | -10.3 M | Reduce 17.75% | 47.73 M | $28.71 |
| Q4 2013 | -20.92 M | Reduce 43.84% | 26.8 M | $30.63 |
| Q1 2014 | -20.06 M | Reduce 74.85% | 6.74 M | $32.12 |
| Q2 2014 | -6.39 M | Reduce 94.82% | 349,508 | $29.68 |
| Q3 2014 | +761,946 | Add 218.01% | 1.11 M | $29.57 |
| Q4 2014 | -1.08 M | Reduce 96.95% | 33,931 | $31.15 |
| Q1 2015 | -836 | Reduce 2.46% | 33,095 | $34.78 |
| Q2 2015 | +5.96 M | Add 18003.62% | 5.99 M | $33.53 |
| Q3 2015 | +302,198 | Add 5.04% | 6.29 M | $31.41 |
| Q4 2015 | -315,499 | Reduce 5.01% | 5.98 M | $32.28 |
| Q1 2016 | -177,224 | Reduce 2.96% | 5.8 M | $29.64 |
| Q2 2016 | +6.48 M | Add 111.72% | 12.28 M | $35.21 |
| Q3 2016 | -5.56 M | Reduce 45.31% | 6.72 M | $33.87 |
| Q4 2016 | -1.27 M | Reduce 18.84% | 5.45 M | $32.48 |
| Q1 2017 | -665,232 | Reduce 12.20% | 4.79 M | $34.21 |
| Q2 2017 | -2,812 | Reduce 0.06% | 4.78 M | $33.59 |
| Q3 2017 | -642,580 | Reduce 13.43% | 4.14 M | $35.70 |
| Q4 2017 | -121,500 | Reduce 2.93% | 4.02 M | $36.22 |
| Q1 2018 | +262,816 | Add 6.54% | 4.28 M | $35.49 |
| Q2 2018 | -1.29 M | Reduce 30.24% | 2.99 M | $36.28 |
| Q3 2018 | -1.96 M | Reduce 65.52% | 1.03 M | $44.07 |
| Q4 2018 | -252,253 | Reduce 24.49% | 777,879 | $43.65 |
| Q1 2019 | -267,032 | Reduce 34.33% | 510,847 | $42.47 |
| Q2 2019 | +5,295 | Add 1.04% | 516,142 | $43.32 |
| Q3 2019 | +23,707 | Add 4.59% | 539,849 | $35.93 |
| Q4 2019 | -166,040 | Reduce 30.76% | 373,809 | $39.18 |
| Q1 2020 | -95,286 | Reduce 25.49% | 278,523 | $32.64 |
| Q2 2020 | -95,338 | Reduce 34.23% | 183,185 | $32.70 |
| Q3 2020 | +2,500 | Add 1.36% | 185,685 | $36.70 |
| Q4 2020 | -20,500 | Reduce 11.04% | 165,185 | $36.81 |
| Q1 2021 | +214,000 | Add 129.55% | 379,185 | $36.23 |
| Q2 2021 | +381,545 | Add 100.62% | 760,730 | $39.16 |
| Q3 2021 | +54,450 | Add 7.16% | 815,180 | $43.01 |
| Q4 2021 | -457,535 | Reduce 56.13% | 357,645 | $59.05 |
| Q1 2022 | -174,323 | Reduce 48.74% | 183,322 | $51.77 |
| Q2 2022 | +636,200 | Add 347.04% | 819,522 | $52.43 |
| Q3 2022 | -9,662 | Reduce 1.18% | 809,860 | $43.76 |
| Q4 2022 | +306,770 | Add 37.88% | 1.12 M | $51.24 |
| Q1 2023 | +338,600 | Add 30.32% | 1.46 M | $40.80 |
| Q2 2023 | +479,118 | Add 32.92% | 1.93 M | $36.68 |
| Q3 2023 | +339,589 | Add 17.56% | 2.27 M | $33.17 |
| Q4 2023 | +321,372 | Add 14.13% | 2.6 M | $28.79 |
| Q1 2024 | -150,264 | Reduce 5.79% | 2.45 M | $27.75 |
| Q2 2024 | +174,969 | Add 7.16% | 2.62 M | $27.98 |
| Q3 2024 | -408,161 | Reduce 15.58% | 2.21 M | $28.94 |
| Q4 2024 | +464,885 | Add 21.02% | 2.68 M | $26.53 |
| Q1 2025 | +203,388 | Add 7.60% | 2.88 M | $25.34 |
| Q2 2025 | -325,720 | Reduce 11.31% | 2.55 M | $24.24 |
| Q3 2025 | -133,144 | Reduce 5.21% | 2.42 M | $25.48 |
Jeremy Grantham's Pfizer Investment FAQs
Jeremy Grantham first purchased Pfizer Inc. (PFE) in Q2 2013, acquiring 58,022,697 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham has held Pfizer Inc. (PFE) for 50 quarters since Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's largest addition to Pfizer Inc. (PFE) was in Q2 2013, adding 58,022,697 shares worth $1.63 B. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
According to the latest 13F filing for Q3 2025, Jeremy Grantham's firm, Grantham, Mayo, Van Otterloo & Co. LLC, owns 2,421,262 shares of Pfizer Inc. (PFE), valued at approximately $61.69 M. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
As of the Q3 2025 filing, Pfizer Inc. (PFE) represents approximately 0.17% of Jeremy Grantham's publicly disclosed stock portfolio, making it one of their key holdings. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Jeremy Grantham's peak holding in Pfizer Inc. (PFE) was 58,022,697 shares, as reported at the end of Q2 2013. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.